Granupas

Granupas is a product that contains the active ingredient aminosalicylic acid. It is supplied in oral form and marketed in the European Union. The preparation is classified among aminosalicylic acids and is used as an anti‑inflammatory agent for gastrointestinal conditions. The product is intended for prescription use under medical supervision and is part of the ATC group A07EC01. No strength or dosage form is publicly listed.

Granupas, containing aminosalicylic acid, is employed in the management of inflammatory bowel disease. Clinical practice in the EU includes its use for specific gastrointestinal conditions where inflammation is a primary concern.

- Ulcerative colitis, particularly mild to moderate disease activity. - Crohn's disease involving the colon or ileocolonic region. - Maintenance therapy to reduce relapse frequency after induction of remission. - Adjunctive treatment when other 5‑ASA agents are insufficient or not tolerated. - Pediatric patients with ulcerative colitis when approved by a specialist. - Patients requiring a non‑steroidal anti‑inflammatory option for intestinal inflammation.

The safety profile of aminosalicylic acid, the active component of Granupas, includes both frequent mild reactions and less common serious events that may require medical attention.

Common: - Nausea or upset stomach - Diarrhea or loose stools - Headache - Skin rash or mild itching

Serious: - Severe allergic reaction (anaphylaxis) with swelling, difficulty breathing - Hepatotoxicity indicated by jaundice or elevated liver enzymes - Blood dyscrasias such as neutropenia or agranulocytosis - Acute pancreatitis presenting with abdominal pain

When prescribing Granupas, clinicians consider several precautionary measures to minimize risk and ensure appropriate patient selection.

- Assess liver function before initiation and monitor periodically. - Evaluate renal function, especially in patients with pre‑existing kidney disease. - Use caution in individuals with a history of hypersensitivity to salicylates. - Avoid use during acute severe ulcerative colitis flare without specialist supervision. - Discuss potential risks with pregnant or breastfeeding women; data are limited. - Review concomitant use of other anti‑inflammatory or immunosuppressive agents. - Consider age‑related dosing adjustments for elderly patients.

Aminosalicylic acid can interact with other medicines, altering its effectiveness or increasing adverse effects.

Avoid: - Concurrent use with systemic corticosteroids at high doses, which may increase gastrointestinal toxicity. - Combination with other salicylate‑containing products, raising risk of salicylate toxicity.

Use with caution: - Anticoagulants such as warfarin, due to potential enhancement of bleeding risk. - Methotrexate, as aminosalicylic acid may affect hepatic metabolism. - Non‑steroidal anti‑inflammatory drugs (NSAIDs), which can exacerbate gastrointestinal irritation. - Live vaccines, because immunomodulatory effects might reduce vaccine efficacy.